Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.

Edwards BJ, Usmani S, Raisch DW, McKoy JM, Samaras AT, Belknap SM, Trifilio SM, Hahr A, Bunta AD, Abu-Alfa A, Langman CB, Rosen ST, West DP.

J Oncol Pract. 2013 Mar;9(2):101-6. doi: 10.1200/JOP.2011.000486.

PMID:
23814519
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH.

J Bone Joint Surg Am. 2013 Feb 20;95(4):297-307. doi: 10.2106/JBJS.K.01181. Review.

PMID:
23426763
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
[PubMed - indexed for MEDLINE]
4.
5.

Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.

Grewal VS, Fayans EP.

Todays FDA. 2008 Aug;20(8):38-41, 43-6.

PMID:
18767452
[PubMed - indexed for MEDLINE]
6.

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.

Sakaeda T, Kadoyama K, Okuno Y.

PLoS One. 2011;6(12):e28124. doi: 10.1371/journal.pone.0028124. Epub 2011 Dec 20.

PMID:
22205938
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.

Clark JA, Humphries JE, Crean S, Reynolds MW.

Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Review.

PMID:
20014051
[PubMed - indexed for MEDLINE]
8.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.

Clin Cancer Res. 2003 Jul;9(7):2394-9.

PMID:
12855610
[PubMed - indexed for MEDLINE]
Free Article
9.

Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.

J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31.

PMID:
17577497
[PubMed - indexed for MEDLINE]
11.

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Migliorati CA, Schubert MM, Peterson DE, Seneda LM.

Cancer. 2005 Jul 1;104(1):83-93.

PMID:
15929121
[PubMed - indexed for MEDLINE]
Free Article
12.

Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.

Henk HJ, Kaura S.

J Med Econ. 2012;15(1):185-94. doi: 10.3111/13696998.2011.649324. Epub 2011 Dec 23.

PMID:
22168786
[PubMed - indexed for MEDLINE]
13.

Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.

Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B.

Breast. 2012 Aug;21(4):544-9. doi: 10.1016/j.breast.2012.04.008. Epub 2012 May 22.

PMID:
22627092
[PubMed - indexed for MEDLINE]
14.

Oral bisphosphonate use in the elderly is not associated with acute kidney injury.

Shih AW, Weir MA, Clemens KK, Yao Z, Gomes T, Mamdani MM, Juurlink DN, Hird A, Hodsman A, Parikh CR, Wald R, Cadarette SM, Garg AX.

Kidney Int. 2012 Oct;82(8):903-8. doi: 10.1038/ki.2012.227. Epub 2012 Jun 13.

PMID:
22695327
[PubMed - indexed for MEDLINE]
15.

Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.

Henk HJ, Kaura S.

J Med Econ. 2012;15(1):175-84. doi: 10.3111/13696998.2011.632044. Epub 2011 Nov 8.

PMID:
22017235
[PubMed - indexed for MEDLINE]
16.

Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.

Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC.

Ann Oncol. 2013 Sep;24(9):2421-5. doi: 10.1093/annonc/mdt233. Epub 2013 Jun 24.

PMID:
23798615
[PubMed - indexed for MEDLINE]
Free Article
17.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
[PubMed - indexed for MEDLINE]
18.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

Support Care Cancer. 2009 Jun;17(6):719-25. doi: 10.1007/s00520-008-0553-7. Epub 2008 Dec 17.

PMID:
19089462
[PubMed - indexed for MEDLINE]
19.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

PMID:
12669777
[PubMed - indexed for MEDLINE]
Free Article
20.

Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system.

Yue Z, Shi J, Jiang P, Sun H.

Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1154-9. doi: 10.1002/pds.3626. Epub 2014 Apr 30.

PMID:
24788910
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk